NCT07582042Recruiting
Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).
Integration of Lesion-tailored, Fundus-controlled Perimetry Into Routine Clinical Care for Patients With Geographic Atrophy (GA) Receiving Pegcetacoplan Treatment in Accordance With the Approved Label.
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
The goal of this observational study is to evaluate changes in retinal sensitivity over time in patients with geographic atrophy due to age related macular degeneration who are receiving pegcetacoplan as part of routine clinical care. The study aims to determine whether lesion tailored fundus-controlled perimetry can reliably measure functional changes near areas of atrophy and whether this testing can be implemented in everyday clinic care over 24 months. Participants will undergo repeated vision testing, standard eye imaging, and visual function questionnaires while continuing their prescribed treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 5 May 2026
- Start date
- 15 Jun 2026
- Primary completion date
- 1 May 2029
- Lead sponsor
- University of Utah
- Diseases
- Macular degeneration
- NCT number
- NCT07582042
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 Jun 2026 to the primary completion date, 1 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently or previously active exudative macular neovascularization in the study eye.
Other illness
- Ocular comorbidities likely to confound sensitivity or imaging (e.g., diabetic retinopathy with macular edema, retinal vein occlusion (RVO), inherited retinal disease, uncontrolled glaucoma).
- Media opacity precluding reliable fundus-controlled perimetry (FCP) or imaging (e.g., dense cataract, corneal opacity, vitreous hemorrhage).
- Any systemic condition judged likely to compromise participation, follow-up, or data integrity.
Other
- High refractive errors (\> ±5.00 Diopters \[D\] spherical equivalent) and significant astigmatism (\> 2.50 D).
Who the study is looking for
- Age 65-90 years.
- Geographic Atrophy (GA) secondary to dry Age-related Macular Degeneration (AMD) in at least one eye with the following criteria:
- GA lesion size between 1 and 15 mm² (≈ 0.4 to 6 disc areas)
- GA borders must be at least 500 μm from the edge of the 30° × 25° optical coherence tomography (OCT) image frame
- No confluent GA extending into peripapillary atrophy
- Receiving intravitreal pegcetacoplan per label (at least one injection before screening).
- Best-corrected visual acuity (BCVA) of 0.1 - 1.0 logMAR (≈ 20/20 to 20/200 Snellen)
- Able to undergo mesopic FCP and required imaging.
- Informed consent provided.
Age in the registry: 65 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah, Department of Ophthalmology, John A. Moran Eye Center Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.